Morgan Stanley analyst Thibault Boutherin lowered the firm’s price target on Novo Nordisk (NVO) to DKK 600 from DKK 700 and keeps an Equal Weight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Stock (NVO) Sees Its Largest Monthly Drop Since 2002
- Novo Nordisk call volume above normal and directionally bullish
- Hold Rating for Novo Nordisk Amid Competitive Pressures and Market Uncertainties
- Novo Nordisk, The United Laboratories announce license agreement for UBT251
- Novo Nordisk price target lowered to DKK 610 from DKK 725 at Berenberg